Eutilex Co Ltd
Eutilex's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a balanced but leveraged position relative to its equity base. The company's liquidity is constrained, with a current ratio of 0.44, suggesting that it holds less in current assets than its current liabilities. Free cash flow is negative at -23,078,155,140 KRW, and operating cash flow is also negative at -14,059,760,650 KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -1.566 and a return on assets of -0.5807. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of -25,630,896,360 KRW and a net loss of -23,923,569,790 KRW further underscore the company's financial challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to sector-specific risks and regional economic fluctuations. Growth trajectory is negative, with the company reporting a net loss and negative cash flows. Historical revenue of 10,294,911,480 KRW does not provide a clear growth pattern, but the current financial performance suggests a lack of momentum. The outlook for the current and next fiscal years is not provided in the data, but the ongoing losses and negative cash flows indicate a challenging near-term environment. Risk factors include medium liquidity risk, as the company's cash and equivalents of 4,397,347,270 KRW are insufficient to cover its short-term obligations. The risk assessment also flags a negative net cash position after subtracting total debt, which could limit the company's ability to fund operations or invest in growth. Dilution risk is currently low, but the company's capital structure and ongoing losses may necessitate future equity raises, which could dilute existing shareholders. Recent events include the company's continued losses and negative cash flows, as disclosed in its latest financial statements. No specific filings or transcripts are provided in the data, but the financial snapshot indicates ongoing operational and financial challenges.
Business. Eutilex Co., Ltd. is a Korea-based company engaged in the production and sale of immunotherapy products, including anticancer T cell therapies and antibody therapies.
Classification. Eutilex is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- Eutilex is operating at a loss with negative cash flows, indicating significant financial distress.
- The company's debt-to-equity ratio is balanced but leveraged, and its liquidity position is weak.
- Profitability metrics are negative, with no clear path to positive returns on equity or assets.
- The company's business is concentrated in a single segment, increasing exposure to sector-specific risks.
- Liquidity risk is medium, and the company's net cash position is negative after accounting for total debt.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.